International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2026
Oral cyclophosphamide combined with bevacizumab in recurrent heavily pre-treated ovarian cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Eyada Mostafa F, Michael Victoria, Patel Shrina, How Jeffrey A, Wilke Roni Nitecki, Jazaeri Amir A, Fleming Nicole D, Soliman Pamela T, Sood Anil K, Westin Shannon N, Sims Travis T
Аннотация
OBJECTIVE: Bevacizumab combined with oral cyclophosphamide has demonstrated activity in recurrent ovarian cancer, but data in heavily pre-treated high-grade disease are limited. We evaluated the safety and efficacy of this combination regimen in this setting.
METHODS: We conducted a retrospective review of patients with recurrent high-grade epithelial ovarian cancer treated with oral cyclophosphamide (50 mg daily) and bevacizumab (15 mg/kg every 3 weeks) at a single institution. Objective response rate was defined as complete or partial response. Progression-free survival was estimated using the Kaplan-Meier method, and adverse events were graded per Common Terminology Criteria for Adverse Events version 5.0.
RESULTS: Among 100 patients (median age 58 years; range; 38-80), 94% had high-grade serous histology and 96% had stage IIIC to IV disease. Fourteen (14%) were platinum-sensitive and 86 (86%) platinum-resistant, with a median of 3 prior treatment lines (range; 1-9). Patients received a median of 5 cycles (range; 2-34). The objective response rate was 40% (95% confidence interval 31 to 51), including 4% complete and 36% partial responses; 20% achieved stable disease. Response did not differ by prior bevacizumab exposure (36% vs 43%, p = .59) or platinum sensitivity status. Median progression-free survival was 4.6 months (95% confidence interval 3.4 to 5.9). Twenty-four (24%) patients experienced adverse events. The most common grade 3 or 4 toxicities included hypertension (3%), thrombocytopenia (3%), and hemorrhagic cystitis (1%).
CONCLUSIONS: Bevacizumab combined with oral cyclophosphamide demonstrated meaningful activity and manageable toxicity in heavily pre-treated high-grade ovarian cancer, supporting its use as a feasible treatment option.
METHODS: We conducted a retrospective review of patients with recurrent high-grade epithelial ovarian cancer treated with oral cyclophosphamide (50 mg daily) and bevacizumab (15 mg/kg every 3 weeks) at a single institution. Objective response rate was defined as complete or partial response. Progression-free survival was estimated using the Kaplan-Meier method, and adverse events were graded per Common Terminology Criteria for Adverse Events version 5.0.
RESULTS: Among 100 patients (median age 58 years; range; 38-80), 94% had high-grade serous histology and 96% had stage IIIC to IV disease. Fourteen (14%) were platinum-sensitive and 86 (86%) platinum-resistant, with a median of 3 prior treatment lines (range; 1-9). Patients received a median of 5 cycles (range; 2-34). The objective response rate was 40% (95% confidence interval 31 to 51), including 4% complete and 36% partial responses; 20% achieved stable disease. Response did not differ by prior bevacizumab exposure (36% vs 43%, p = .59) or platinum sensitivity status. Median progression-free survival was 4.6 months (95% confidence interval 3.4 to 5.9). Twenty-four (24%) patients experienced adverse events. The most common grade 3 or 4 toxicities included hypertension (3%), thrombocytopenia (3%), and hemorrhagic cystitis (1%).
CONCLUSIONS: Bevacizumab combined with oral cyclophosphamide demonstrated meaningful activity and manageable toxicity in heavily pre-treated high-grade ovarian cancer, supporting its use as a feasible treatment option.